MarketCap
Facebook
X
Telegram
Cardiovascular Systems Revenue | CSII
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 236 M | 259 M | 237 M | 248 M | 60.2 M | 52.6 M | 178 M | 182 M | 137 M | 104 M | 82.5 M | 78.8 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 259 M | 52.6 M | 155 M |
Quarterly Revenue Cardiovascular Systems
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.5 M | 59.7 M | 61.5 M | 56.2 M | 59.1 M | 58.4 M | 59.1 M | 58.4 M | 63.3 M | 63.3 M | 64.2 M | 60.5 M | 68.3 M | 64.5 M | 68.3 M | 63.3 M | 60.2 M | 56.3 M | 60.2 M | 56.3 M | 60.2 M | 56.3 M | 52.6 M | 49.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 68.3 M | 49.7 M | 60.1 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
64.1 M | - | - | $ 162 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | USA |
 |
AxoGen
AXGN
|
225 M | $ 48.73 | 1.42 % | $ 2.24 B | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
1.64 B | $ 18.34 | 0.55 % | $ 1.41 B | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
IRIDEX Corporation
IRIX
|
52.7 M | $ 0.86 | 3.87 % | $ 14.6 M | USA |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | USA |
 |
LivaNova PLC
LIVN
|
1.39 B | $ 82.22 | 0.02 % | $ 4.48 B |  Britain |
 |
LENSAR
LNSR
|
58.4 M | $ 8.2 | 0.24 % | $ 98.1 M | USA |
 |
Avanos Medical
AVNS
|
701 M | $ 24.99 | - | $ 1.16 B | USA |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | USA |
 |
MiMedx Group
MDXG
|
419 M | $ 4.27 | 1.67 % | $ 631 M | USA |
 |
ClearPoint Neuro
CLPT
|
37 M | $ 15.34 | 0.1 % | $ 434 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.4 | 10.38 % | $ 24.9 M | USA |
 |
SmileDirectClub
SDC
|
471 M | - | -53.45 % | $ 9.71 M | USA |
 |
Sientra
SIEN
|
25.1 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
177 M | - | - | $ 1.07 B | USA |
 |
NanoVibronix
NAOV
|
2.55 M | - | - | $ 1.08 M | USA |
 |
Surgalign Holdings
SRGA
|
82 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
730 M | - | - | $ 12.3 B | USA |
 |
Inogen
INGN
|
349 M | $ 5.75 | 0.17 % | $ 153 M | USA |
 |
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | USA |
 |
Natus Medical Incorporated
NTUS
|
473 M | - | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M | USA |
 |
ThermoGenesis Holdings
THMO
|
9.44 M | - | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
2.13 M | - | 3.55 % | $ 7.96 M | USA |
 |
Titan Medical
TMDI
|
20.1 M | - | -26.32 % | $ 19.6 M | Canada |
 |
Butterfly Network
BFLY
|
97.6 M | $ 8.84 | 0.79 % | $ 2.18 B | USA |
 |
Vapotherm
VAPO
|
68.7 M | - | 6.72 % | $ 34 M | USA |